Theravance Biopharma to Announce Q2 2024 Financial Results on August 5, 2024

Theravance Biopharma, Inc. (NASDAQ: TBPH) is set to announce its financial results for the second quarter of 2024 and provide a business update after the market closes on Monday, August 5, 2024. The company will host a conference call and webcast at 5:00 pm ET (2:00 pm PT/10:00 pm IST) on the same day.

Theravance Biopharma is dedicated to improving patient lives through innovative medicine. The company's expertise has resulted in the development of YUPELRI® (revefenacin) inhalation solution, which is FDA-approved for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Another notable development is Ampreloxetine, a late-stage investigational once-daily norepinephrine reuptake inhibitor aimed at treating symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). Ampreloxetine has the potential to be a pioneering therapy effective in addressing various cardinal symptoms in MSA patients.

Theravance Biopharma is committed to driving shareholder value through its developments and innovations. The company holds registered trademarks, including THERAVANCE BIOPHARMA®, THERAVANCE®, and the Cross/Star logo. YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!